374 related articles for article (PubMed ID: 14701768)
1. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Soulieres D; Senzer NN; Vokes EE; Hidalgo M; Agarwala SS; Siu LL
J Clin Oncol; 2004 Jan; 22(1):77-85. PubMed ID: 14701768
[TBL] [
